Design Therapeutics (DSGN) Interest Coverage Ratio: History & Chart

Design Therapeutics, Inc.(DSGN)

Biotechnology · Carlsbad, CA

$11.94-0.48 (-3.90%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

Carlsbad, CA

55 employees

www.designtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pratik Shah

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Design Therapeutics, Inc. (DSGN)	$745.42M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$742.96M	-22.78x	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$762.81M	-85.20x	23.14x	23.14x	23.14x
Attovia Therapeutics, Inc. (ATTO)vs ›	$756.25M	N/A	N/A	N/A	N/A
Geron Corporation (GERN)vs ›	$769.83M	-1.65x	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$716.99M	N/A	578.36x	578.36x	578.36x
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$772.90M	-5.87x	6.84x	6.84x	3.53x
Anteris Technologies Global Corp. (AVR)vs ›	$708.82M	-1286.22x	N/A	N/A	N/A
Collegium Pharmaceutical, Inc. (COLL)vs ›	$715.49M	2.27x	2.29x	1.77x	1.65x
Achieve Life Sciences, Inc. (ACHV)vs ›	$713.99M	-67.01x	15.61x	8.76x	6.40x

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Design Therapeutics, Inc. (DSGN)

$745.42M

N/A

Candel Therapeutics, Inc. (CADL)vs ›

$742.96M

-22.78x

N/A

Cytek Biosciences, Inc. (CTKB)vs ›